Trial reportDrug design, development and therapy2026
Effect of Anterior Quadratus Lumborum Block at the Lateral Supra-Arcuate Ligament Combined with Esketamine on the Quality of Postoperative Recovery After Laparoscopic Radical Surgery for Elderly Patients with Colorectal Cancer: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative pain, opioid exposure and slow recovery remain common concerns in elderly patients undergoing laparoscopic radical resection of colorectal cancer. We assessed whether anterior quadratus lumborum block at the lateral supra-arcuate ligament (QLB-LSAL) combined with low-dose esketamine improves recovery quality. Methods: In this single-centre, randomized, placebo-controlled trial with blinded outcome assessment, 90 patients aged ≥60 years were assigned to QLB-LSAL with a saline infusion (Group Q), esketamine alone (Group E), or QLB-LSAL with esketamine (Group QE). The prespecified primary endpoint was the QoR-40 total score on postoperative day 3. Esketamine 0.2 mg/kg was given intravenously before induction, followed by 0.2 mg/kg/h until 30 min before the end of surgery in Groups E and QE; Group Q received an equal volume of saline. Longitudinal data were analysed with linear mixed-effects models, with Tukey post-hoc testing and Benjamini-Hochberg correction. Results: Eighty-eight patients were analysed (Q=29, E=30, QE=29). On day 3 the QoR-40 total score was higher in Group QE than in Group E (adjusted difference 8.30, 95% CI 4.37-12.23, Tukey P<0.001); the corresponding day-1 difference was 12.07 (95% CI 7.66-16.47, P<0.001). Group QE also showed better comfort and pain scores, lower remifentanil consumption and fewer day-1 pump activations than Group E, and a higher day-1 QoR-40 score than Group Q (P=0.006). Between-group differences in HADS anxiety scores were not significant after adjustment for multiplicity (QE vs Q on day 1, P=0.068). The incidence of adverse events did not differ between groups. Conclusion: In elderly patients undergoing laparoscopic colorectal cancer surgery, QLB-LSAL combined with low-dose esketamine improved the prespecified day-3 recovery endpoint and reduced early postoperative pain and opioid use compared with esketamine alone; any anxiolytic effect was not confirmed after multiplicity adjustment. Trial registration: ChiCTR2400082301.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.